Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma
Reid W. Merryman(Harvard University), Viktor A. Adalsteinsson(Broad Institute), Ju Cheng(Broad Institute), Robert Redd(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Timothy Blewett(Broad Institute), Alex F. Herrera(City of Hope), Katherine Antel(University of Cape Town), Mark A. Murakami(Harvard University), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Philippe Armand(Harvard University), Hyun Hwan An(Dana-Farber Cancer Institute), Justin Rhoades(Broad Institute), Kan Xiong(Broad Institute), Andjela Crnjac(Broad Institute), Sainetra Sridhar(Broad Institute), Yi‐Bin Chen(Massachusetts General Hospital), Mikaela M. McDonough(Dana-Farber Cancer Institute), Liliana Guerrero(Dana-Farber Cancer Institute)
Cited by 4
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|1k